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Abstract
Background Current evidence supports the involvement of brain-derived neurotrophic factor (BDNF) Val66Met polymor-
phism, and the ε4 allele of APOE gene in hippocampal-dependent functions. Previous studies on the association of Val66Met 
with whole hippocampal volume included patients of a variety of disorders. However, it remains to be elucidated whether 
there is an impact of BDNF Val66Met polymorphism on the volumes of the hippocampal subfield volumes (HSv) in cogni-
tively unimpaired (CU) individuals, and the interactive effect with the APOE-ε4 status.
Methods BDNF Val66Met and APOE genotypes were determined in a sample of 430 CU late/middle-aged participants from 
the ALFA study (ALzheimer and FAmilies). Participants underwent a brain 3D-T1-weighted MRI scan, and volumes of the 
HSv were determined using Freesurfer (v6.0). The effects of the BDNF Val66Met genotype on the HSv were assessed using 
general linear models corrected by age, gender, education, number of APOE-ε4 alleles and total intracranial volume. We 
also investigated whether the association between APOE-ε4 allele and HSv were modified by BDNF Val66Met genotypes.
Results BDNF Val66Met carriers showed larger bilateral volumes of the subiculum subfield. In addition, HSv reductions 
associated with APOE-ε4 allele were significantly moderated by BDNF Val66Met status. BDNF Met carriers who were also 
APOE-ε4 homozygous showed patterns of higher HSv than BDNF Val carriers.
Conclusion To our knowledge, the present study is the first to show that carrying the BDNF Val66Met polymorphisms 
partially compensates the decreased on HSv associated with APOE-ε4 in middle-age cognitively unimpaired individuals.
Keywords APOE-ε4 · BDNF · Hippocampal subfields · Imaging genetics · Subiculum · Val66Met
Introduction
Brain-derived neurotrophic factor (BDNF) is a neurotro-
phin involved in neurogenesis and synaptic plasticity in the 
central nervous system, especially in the hippocampus, and 
has been implicated in the pathophysiology of several neu-
ropsychiatric disorders (Bathina and Das 2015; Autry and 
Monteggia 2012; Numakawa et al. 2018). The single nucleo-
tide polymorphism (SNP) rs6265 (also known as Val66Met), 
causes a valine (Val) to methionine (Met) substitution at 
codon 66 of BDNF protein. Particularly, the study of Val-
66Met polymorphism within the BDNF gene is of special 
interest because of its documented impact on hippocampal-
dependent functions (Notaras and van den Buuse 2018; Toh 
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et al. 2018; Egan et al. 2003; Hariri et al. 2003). Hence, 
extensive research focuses on the discovery of associa-
tions between BDNF Val66Met polymorphism and several 
hippocampal phenotypes. However, recent meta-analyses 
addressing hippocampal volumes for BDNF Val66Met have 
reported inconsistent statistically significant associations, as 
well as inconsistencies regarding the direction of the geno-
type effects across individual studies (Harrisberger et al. 
2014, 2015).
Two recent large meta-analyses suggest that the analy-
sis of hippocampal subfield volumes may allow for more 
accurate detection of genetic effects in genetic association 
analyses, compared with whole hippocampal volume (van 
der Meer et al. 2018; Hibar et al. 2017). Moreover, previ-
ous studies have shown that different pathological condi-
tions affect subfields differently (West et al. 1994; Jin et al. 
2004; Ezzati et al. 2014; Mueller et al. 2010; Hett et al. 
2018). In fact, the proven differential expression of BDNF 
and its receptors in different regions of the hippocampus 
(Kowiański et al. 2018; Vilar and Mira 2016; Franzmeier 
et al. 2019), reinforces distinct biological functions of BDNF 
Val66Met polymorphism on the different subfields. How-
ever, to our knowledge no previous studies have addressed 
the effects of the BDNF Val66Met polymorphism on hip-
pocampal subfields in cognitively unimpaired (CU) indi-
viduals. Most of the studies addressing the association of 
BDNF Val66Met polymorphism and hippocampal volumes 
(subfields and/or whole hippocampus) included patients of a 
variety of neuropsychiatric disorders, such as major depres-
sive disorder, schizophrenia and bipolar disorder (Zeni et al. 
2016; Cao et al. 2016; Reinhart et al. 2015; Aas et al. 2014; 
Frodl et al. 2014), showing also inconsistencies concerning 
the impact of the BDNF Val66Met polymorphisms (Tsai 
2018).
The ε4 allele of apolipoprotein E (APOE) gene, the major 
genetic risk factor for Alzheimer’s disease (AD) (Mueller 
and Weiner 2009), has also an impact on hippocampal sub-
fields. APOE ε4-carriers have reduced volume of the subicu-
lar/CA1 region in AD patients (Pievani et al. 2011), as well 
as in a pool of older adults that included healthy controls and 
patients with amnestic mild cognitive impairment (aMCI) 
and AD dementia, after controlling for the diagnostic group 
(Kerchner et al. 2014). In a recent report in CU partici-
pants, we also showed that APOE-ε4 relates to significantly 
reduced hippocampal tail in a gene dose-dependent manner 
(Cacciaglia et al. 2018a).
Moreover, recent evidence suggests that APOE geno-
types differentially affects the expression of BDNF through 
the regulation of its maturation in human astrocytes and its 
secretion (Sen, Nelson, and Alkon 2015). Astrocytes are 
known to synthesise BDNF, and as brain APOE is primarily 
produced by astrocytes, studying APOE and BDNF modula-
tion becomes important. Specifically, interactions between 
APOE-ε4 and BDNF have been suggested to influence their 
secondary effects on AD pathology (Álvarez et al. 2014), 
and their influence on hippocampal volume (Li et al. 2016; 
Shi et al. 2014; Liu et al. 2015a, b). In addition, a significant 
combined effect of APOE-ε4 and BDNF Val66Met poly-
morphisms has been reported to moderate β-amyloid-related 
cognitive decline in preclinical AD (Lim et al. 2015). Epi-
sodic memory performance was also found to be impaired 
in MCI/AD individuals who were also carriers of both the 
APOE-ε4 and BDNF Met polymorphisms (Gomar et al. 
2016), as well as in healthy individuals (Ward et al. 2014). 
Overall, evidence suggests biological interactions between 
APOE and BDNF for memory and other brain-related pro-
cesses that may help to explain the increased AD risk in 
APOE-ε4 carriers during the period that precedes the devel-
opment of symptoms.
Therefore, the aim of the present study is to evaluate the 
impact of Val66Met polymorphism on hippocampal sub-
fields in a large sample of in middle-age cognitively unim-
paired individuals CU participants and to assess whether an 
interactive effect with the APOE-ε4 genotype exists.
Materials and methods
Study population and setting
Participants were drawn from the ALFA study (Alzhei-
mer and FAmilies) established at the Barcelonaβeta Brain 
Research Center (Molinuevo et al. 2016), which aims at 
identifying the neuroimaging and cognitive signatures in 
preclinical AD. The ALFA study (Clinicaltrials.gov Identi-
fier: NCT01835717) entangles a cohort of 2,743 cognitively 
unimpaired participants, mostly adult children of patients 
with AD, and aged between 45 and 75 years. Cognitive sta-
tus was assessed at baseline as follows: Mini-Mental State 
Examination (Folstein et al. 1975; Blesa et al. 2001) > 26, 
Memory Impairment Screen (Buschke et al. 1999; Böhm 
et al. 2005) > 6, Time-Orientation subtest of the Barcelona 
Test II (Quinones-Ubeda 2009) > 68, semantic fluency 
(Ramier and Hecaen 1970; Peña-Casanova et  al. 2009) 
(animals) > 12 and Clinical Dementia Rating scale (Morris 
1993) = 0. A subset of 430 participants from the ALFA study 
with available information on BDNF Val66Met polymor-
phisms and APOE genotypes, as well as neuroimaging data 
(HSv) were included in this study (Fig. 1). The cognitive 
status of these participants was reviewed if cognitive test-
ing had not been conducted in the last 6 months. For this, 
mild cognitive impairment (MCI) was ruled out by clinical 
judgment after interview and accounting for psychometric 
scores in the main variables of the Free and Cued Selec-
tive Reminding Test [FCSRT] (Buschke et al. 2017). The 
study was conducted in accordance with the directives of 
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the Spanish Law 14/2007, of 3rd of July, on Biomedical 
Research (Ley 14/2007 de Investigación Biomédica). All 
participants accepted the study procedures by signing an 
informed consent form. A subset of 430 participants from 
the ALFA study with available information on BDNF Val-
66Met polymorphisms and APOE genotypes, as well as neu-
roimaging data (HSv) were included in this study (Fig. 1).
Genotyping
DNA samples were obtained from whole blood samples by 
applying salting out protocol. DNA was eluted in 800 µl of 
H2O (milliQ) and quantified using Quant-iTT PicoGreen® 
dsDNA Assay Kit (Life Technologies). Integrity of DNA 
was checked in a subset of samples by running a 1% aga-
rose gel. All the samples were within specification. Genome-
wide genotyping was performed using the NeuroChip 
backbone(Blauwendraat et al. 2017), based on a genome-
wide genotyping array (Infinium HumanCore-24 v1.0) con-
taining 306,670 tagging variants and a custom content that 
has been updated and extended with 179,467 neurodegen-
erative disease-related variants at the Cancer Epigenetics 
and Biology Program (PEBC; IDIBELL). Previous step was 
to normalize the quantity of DNA from each sample. The 
analysis was performed by the GenomeStudio (Illumina) 
software using the genotyping module (standard analysis). 
PLINK was used for genetic data quality control (Purcell 
et al. 2007). We applied the following sample quality con-
trol thresholds: sample call rate > 97% (N = 6 exclusion) and 
heterozygosity 5 SD (N = 8 exclusions). Then, we checked 
sex discordances (N = 4 exclusions). In total, we excluded 
18 subjects (less than 2%). None of the individuals pre-
sented autosomal dominant mutations in APP, PSEN1, and 
PSEN2. The final genetic data set consisted of volunteers of 
European ethnic origin with available information regarding 
BDNF Val66Met polymorphism and the APOE rs429358 
and rs7412 polymorphisms. Genotype and allele frequen-
cies of Val66Met, rs429358 and rs7412 polymorphisms were 
determined. Moreover, allele frequencies were inspected 
for potential covariate-related differences. Departures from 
Hardy–Weinberg equilibrium were also examined (Ryck-
man and Williams 2008). The APOE allelic variants were 
obtained from allelic combinations of the rs429358 and 
rs7412 polymorphism (Radmanesh et al. 2014). According 
to the genotypes of these polymorphisms, subjects were clas-
sified depending on the number of ε4 alleles (non-carriers, 
one ε4 allele or two ε4 alleles).
Image acquisition and extraction of hippocampal 
subfield volumes
Scans were obtained with a 3 T scanner (Philips Ingenia 
CX). The MRI protocol was identical for all participants 
and included high-resolution three-dimensional struc-
tural images weighted in T1 with an isotropic voxel of 
0.75 × 075 × 0.75 mm3. The acquisition parameters were 
TR/TE/TI = 9.9/4.6/900 ms, flip angle = 8° and a matrix 
size of 320 × 320 × 240. Hippocampal subfields were seg-
mented using FreeSurfer version 6.0 (Iglesias et al. 2015). 
We extracted raw volumes for 12 different HSv per hemi-
sphere: the cornu ammonis region 1 (CA1), cornu ammonis 
region 2/3 (CA3), cornu ammonis region 4 (CA4), dentate 
gyrus (DG), fimbria, hippocampal-amygdaloid transition 
area (hata), tail, parasubiculum, presubiculum, subiculum, 
fissure and molecular layer. The value of the subfields used 
as the outcomes of the study were calculated as the sum of 
the regional value of each hemisphere  (mm3). We visually 
inspected the segmentation of the individuals included in 
the study (Fig. 2), and we removed outliers and/or abnormal 
hippocampal subfields volume values. The whole hippocam-
pal volume, as well as, total intracranial volume were also 
calculated using Freesurfer (v. 6.0).
Statistical analysis
Differences in demographic variables were tested using 
χ2  test and F test for gender, age, education, number of 
APOE-ε4 carriers and total intracranial volume (TIV). The 
additive, dominant, recessive, and codominant effects of the 
BDNF Val66Met genotype on the hippocampal subfields 
volume were assessed using general linear models corrected 
by age, sex, years of education, number of APOE-ε4 alleles 
ALFA Study sample
N =  2,743
No genetic data or data excluded after
applying quality control criteria 
(N = 1,805).
Genetic data
N =  938
No neuroimaging data acquired/pre-processed
or data excluded after quality control criteria 
(N= 508).
Neuroimaging data
N = 430 
   SNP: rs6265/Val66Met (BDNF)
ROIS: Hippocampal subfield volumes
(12 structures) and whole hippocampus
rs7412, rs429358 (APOE)
Fig. 1  Flow chart depicting the final sample size of the real appli-
cation. Solid lines and boxes represent individuals remaining in the 
study. Dashed lines and boxes represent individuals excluded. Rea-
son and number of individuals excluded is indicated in dashed boxes. 
SNP single nucleotide polymorphism, N size of the sample, ROIS 
brain regions of interest
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and TIV. These covariates were selected based on previous 
associations reported using the ALFA study sample (Cac-
ciaglia et al. 2018b). In brief, the genetic additive model 
predicts a linear increase of the phenotypic variable depend-
ing on the number of Met alleles, whereas the codominant 
genetic model infers that the heterozygote mean differs from 
both the homozygote means. The dominant genetic model 
assumes a common response to 1 or 2 copies of the Met 
allele. Finally, a recessive genetic model predicts a common 
response to 0 or 1 copies of the Met allele.
The assumption of different genetic models was per-
formed to counteract a misspecification of the true underly-
ing genetic model, which could have an adverse effect on 
the statistical power of an association, and on the effect size 
Fig. 2  T1 images of hippocampal segmentation
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(Gaye and Davis 2017). The goodness-of-fit of each genetic 
model was evaluated based on the Akaike information cri-
terion (AIC), for which lower numerical values indicate a 
better fit of the model (Akaike 1998).
We also investigated whether the association between 
BDNF Val66Met and hippocampal subfield volumes was 
modified by the number of APOE-ε4 alleles, with a sec-
ond model that included an interaction term between BDNF 
Val66Met polymorphism and the number of ε4 alleles, co-
varying for age, sex, years of education and total intracra-
nial volume potential confounders. In this model, dominant 
genetic effects were assumed for Val66Met polymorphism 
and additive genetic effects for APOE-ε4 alleles.
Moreover, in post-hoc analyses, we evaluated the effects 
of BDNF Val66Met and APOE-ε4 status on cognitive 
performance.
Statistical significance was set at False Discovery Rate 
(FDR) corrected p value < 0.05, and all statistical analyses 




Descriptive data of the demographic and BDNF Val66Met 
polymorphism information are presented in Tables 1 and 
2. The mean age of the population was 57.1 ± 5.7 years 
old, with 61.4% women. The BDNF Val66Met genotype 
groups did not significantly differ in the distribution of 
gender (χ2[2] = 0.55, p: 0.51), number of APOE-ε4 alleles 
(χ2[2] = 6.13, p = 0.19), age (F[2,427] = 0.67, p: 0.76), years 
of education (F[2,247] = 0.107, p: 0.9), or total intracranial 
volume (TIV) (F[2,427] = 1.66, p: 0.19). The distribution of 
BDNF Val66Met and APOE rs429358 and rs7412 polymor-
phisms did not deviate from Hardy–Weinberg equilibrium 
(χ2[1] = 0.42, p: 0.51). Table 3 summarizes the hippocampal 
subfield volumes analyzed in the study by BDNF genotype. 
All morphometric subfield measures were normally distrib-
uted (Kolmogorov Smirnov test, FDR > 0.05) and their vari-
ances were homogenous (Levene’s test, FDR > 0.05). Figure 
S1 shows the pattern of correlation (Pearson correlation sta-
tistics) among all subfields included in the study. Hippocam-
pal subfield structures present high correlation among them 
(r > 0.8) (i.e., structural covariance).
Effect of BDNF Val66Met polymorphism 
on hippocampal subfields
General linear models revealed that Met carriers showed 
statistically significant larger bilateral volumes of the sub-
iculum under the dominant model ( dom = 2.53%, pFDRdom 
= 3 × 10−3 ) (Table 4 and Fig. 3). For subiculum subfield, 
an additive genetic model obtained the lowest AICs score 
(AIC = 4890.43), indicating that this model is the most par-
simonious model for this subfield structure. Moreover, we 
found statistically significant larger bilateral volumes of the 
subiculum under the additive genetic model ( add = 2.39%, 
pFDRadd = 0.013) (Table S1). No significant results after 
FDR-correction were found under recessive and codominant 
genetic models. In addition, nominal significant results with-
out FDR adjustment (p < 0.05) showed larger bilateral vol-
umes of the molecular layer of the hippocampus (β: 1.55%, 
p: 0.007), presubiculum (β: 1.74%, p: 0.041), and whole hip-
pocampal volume (β: 1.46%, p: 0.025) for Met carriers under 
the dominant genetic model. Results of all adjusted genetic 
models for each HSv can be found in Table S1.
Effect of the interaction between APOE‑ε4 and BDNF 
Val66Met on hippocampal subfields
As expected, APOE ε4 allele was associated with lower 
bilateral volumes of the hippocampal subfields, even though 
on a trend-level (Table S2). Interestingly, when this associa-
tion was studied according to BDNF Val66Met genotypes, 
Table 1  Characteristics of the study according to rs6265 (Val/Met) status
Mean and SD are shown for continuous variables







Total (n = 430) Statistic p
Age (m ± SD; years) 57.31 (5.63) 56.93 (5.84) 55.97 (5.82) 57.1 (5.72) F (2.427) = 0.67 0.76
Sex (female), n (%) 154 (62.35%) 98 (60.87%) 12 (54.55%) 264 (61.4%) Chi (2) = 0.549 0.512
Education (m ± SD; 
years)
13.87 (± 3.53) 14.03 (± 3.53) 13.95 (± 3.5) 13.93 (± 3.52) F (2.427) = 0.107 0.899
Number of APOE-ε4 
alleles, n (%)
0: 160 (64.78%); 1: 
75 (30.36%); 2: 12 
(4.86%)
0: 89 (55.28%); 1: 
59 (36.65%); 2: 13 
(8.07%)
0: 12 (54.55%); 1: 
7 (31.82%); 2: 3 
(13.64%)
0: 261 (60.7%); 1: 
141 (32.79%); 2: 28 
(6.51%)
Chi (2) = 6.129 0.19
TIV (m ± SD;  cm3) 1442.91 (± 177.13) 1453.1 (± 163.66) 1511.62 (± 163.28) 1450.24 (± 171.79) F (2.427) = 1.656 0.192
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we observed a significant interaction with the presence of 
Met alleles (p < 0.05) (Table 5). APOE-ε4 homozygotes 
carrying at least one Met allele presented nominally sig-
nificant larger bilateral volumes of the CA4 (β: 7.25%, p: 
0.016) and DG (β: 7.38%, p: 0.012) subfields, hippocampal 
tail (β: 8.33%, p: 0.05), and whole hippocampal volumes 
(β: 5.35%, p: 0.046) than the expected combined effect of 
the individual contribution of APOE-ε4 (reverse effect) and 
BDNF Val66Met (Fig. 4). Moreover, even though the results 
for the remainder hippocampal subfields were statistically 
not significant, changes on hippocampal subfields volumes 
follow the same general patterns (Figure S2). 
Post‑hoc analyses: Effect of BDNF Val66Met 
and APOE‑ε4 on cognitive performance
The post hoc analyses, although not significant, suggested 
better cognitive performance patterns for Met carriers in 
most FCSRT domains, and in depression scores of the Hos-
pital Anxiety and Depression Scale (HADS) (Table 6). In 
addition, APOE-ε4 status did not significantly influence 
the effects of BDNF Val66Met genotypes on cognitive 
performance.
Discussion
To the best of our knowledge, this is the first study to show a 
phenotypic effect of the BDNF Val66Met polymorphism in 
the hippocampal subfields of cognitively unimpaired (CU) 
individuals. Moreover, the present study is also the first in 
CU to find an effect modification by BDNF Val66Met poly-
morphism of associations between APOE-ε4 status and hip-
pocampal subfield volumes.
We first found significantly larger bilateral subiculum vol-
umes in CU middle-aged/late-middle-aged BDNF Val66Met 
carriers in a dose-dependent manner. The direction of the 
effects is consistent across different subfields and the entire 
hippocampal formation, as shown by the nominally signifi-
cant difference between BDNF Val66Met carriers and non-
carriers involving the molecular layer of the hippocampus, 
as well as the pre-subiculum and the whole hippocampus.
Given that BDNF Val66Met polymorphism has been 
related to impaired hippocampal long-term potentiation 
which underlies learning and memory (Spriggs et  al. 
2018), our results may underline compensatory mecha-
nisms in the Met-carriers to achieve normative episodic 
recall, which is highly specialized in the subiculum 
(Eldridge et  al. 2005; Suthana et  al. 2015). However, 
although most studies showed that large hippocampal vol-
umes lead to better memory performance and may protect 
from dementia (Pohlack et al. 2014; Whitwell 2010; Erten-
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cognitive performance in middle-aged CU individual’s 
remains controversial. For instance, smaller hippocampal 
volumes have been related to better episodic memory, due 
to efficient synaptic pruning (Van Petten 2004). Thus, our 
results could suggest a moderating role of BDNF in the 
neurobiology of hippocampal subfields, which may stress 
the importance to consider the hippocampal formation at 
the subfield level to disentangle potential opposite effects 
leading to the aforementioned conflicting results. In addi-
tion, we cannot rule out that the BDNF Val66Met poly-
morphism may differentially influence the morphology of 
other brain areas. This calls for additional whole-brain 
voxel-wise studies addressing distinct genetic models of 
penetrance of BDNF Val66Met.
Second, we also observed that Met-carriers compensate 
for the deleterious impact of the number of APOE-ε4 alleles 
on hippocampal subfield volumes. As expected, we observed 
that APOE-ε4 homozygotes showed a tendency towards dis-
playing reduced volumes of the subiculum and hippocampal 
tails, in accordance with previous reports (Kerchner et al. 
2014; Cacciaglia et al. 2018a; Pievani et al. 2011). These 
individuals are at increased higher risk (× 15) to develop 
AD as compared to APOE-ε4 non-carriers. The lower hip-
pocampal volumes in APOE-ε4 carriers are often inter-
preted as brain marker that confers vulnerability towards 
developing the clinical picture of AD. Strikingly, we found 
that APOE-ε4 homozygotes who were also Met-carriers 
countered the effect of the APOE genotype and presented 
HSv within the ranges expected for APOE-ε4 non-carriers, 
particularly in the CA4, GC-ML-DG and the hippocampal 
tails. It could be argued that Met-carriers can counter the 
deleterious effect of the APOE-ε4 genotype in the age range 
of the studied sample.
Another possible explanation to this finding could raise 
from an interaction of the BDNF Val66Met polymorphism 
with pathological markers of AD, as the APOE-ε4 allele 
has also been strongly linked to a dose-dependent increase 
in the prevalence of abnormally elevated cerebral amy-
loid deposition in CU individuals (Reiman et al. 2009). 
By the mean age of our APOE-ε4 homozygote group 
(56.62 ± 5.71y), about half of them are expected to display 
abnormally high amyloid levels (Jansen et al. 2015). How-
ever, previous longitudinal reports on amyloid-positive 
CU individuals have described that the BDNF Val66Met 
allele was associated with a steeper decline in cognitive 
function and hippocampal atrophy (Yen Ying Lim et al. 
2013). Moreover, this deleterious effect is more severe in 
APOE-ε4 carriers (Lim et al. 2015). These studies, how-
ever, were performed in significantly older cohorts (aver-
age age of 70y) than that in our work. Another recent study 
performed in subjects with an age range similar to ours 
(55y) confirmed this longitudinal pattern of decline in 
cognition, particularly in amyloid-positive CU individu-
als (Boots et al. 2017). However, in this work, Boots et al. 
also reported that, at baseline, Met carriers showed a sig-
nificantly better cognitive performance (verbal learning 
and memory, speed and flexibility, and working memory), 
even if amyloid positive. Similar patterns of effect were 
observed in our sample. Specifically, we found that Met 
carriers suggested patterns of better cognitive performance 
on the Free and Cued Selective Reminding Test (FCSRT) 
domains, and on the Depression score of the Hospital 
Table 4  Main effects of Val66Met genotype on hippocampal subfields  (mm3)
All models were adjusted by sex, years of education, number of APOE-ε4 allele and total intracranial volume
CA1 cornu ammonis region 1, CA3 cornu ammonis region 23, CA4 cornu ammonis region 4, GC-ML-DG granule cells in the molecular layer of 
the dentate gyrus, hata hippocampal-amygdaloid transition region, HP hippocampus, CI95 confidence interval, FDR95 false discovery rate cor-
rected p value < 0.05. AIC akaike information criterion
Hippocampal subfield Best genetic model Effect  (mm3) CI 95% Effect (%) p value FDR95% AIC
CA1 Dominant 18.575 (− 0.67, 37.82) 1.54% 0.059 0.531 5188.564
CA3 Recessive 14.291 (− 1.43, 30.01) 3.93% 0.076 0.684 4321.049
CA4 Recessive 14.04 (− 0.69, 28.77) 3.07% 0.062 0.671 4264.9
GC-ML-DG Recessive 16.756 (− 0.19, 33.71) 3.11% 0.053 0.636 4385.858
Subiculum Additive 19.435 (8.06, 30.81) 2.39% 0.001 0.013* 4890.434
Presubiculum Dominant 10.556 (0.44, 20.67) 1.74% 0.041 0.41 4635.326
Parasubiculum Dominant 1.845 (− 1.06, 4.75) 1.46% 0.214 1 3562.288
Hippocampal fissure Dominant 5.226 (− 2.05, 12.5) 1.52% 0.16 1 4351.502
Hippoccampal tail Dominant 12.37 (− 9.43, 34.17) 1.15% 0.267 1 5295.52
Fimbria Recessive 1.601 (− 10.09, 13.29) 0.91% 0.789 1 4065.996
Hata Dominant 0.333 (− 1.95, 2.61) 0.28% 0.775 1 3354.183
Molecular layer Additive 16.578 (4.59, 28.57) 1.55% 0.007 0.084 4937.902
Whole hippocampus Dominant 95.904 (12.06, 179.75) 1.46% 0.025 0.275 6454.188
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Anxiety and Depression Scale (HADS). Although these 
differences were not statistically significant, one poten-
tial explanation to reconcile our findings with the existing 
literature would be that the Met genotype might provide 
a limited beneficial effect during middle age. When no 
longer capable of compensating for the deleterious down-
stream effects of amyloid accumulation, then Met carri-
ers would experience faster hippocampal atrophy and a 
steeper decline in cognition. Neither shall it be excluded 
that APOE-ε4 and Met carriers could be the most vulner-
able to an inflammatory response at the beginning of the 
amyloid-pathology. Nevertheless, the current unavailabil-
ity of core AD biomarkers and the cross-sectional nature 
of this study constitute a limitation for the full inter-
pretation of the interaction between the BDNF Met and 
APOE-ε4 genotypes. Nevertheless, this will be mitigated 
in the longitudinal follow-up of the cohort here studied, as 
a subset of our participants will undergo a lumbar puncture 
to assess cerebrospinal fluid levels of core AD biomarkers 
(Aβ42, total Tau, and phosphorylated Tau).
A strong feature of our study that may sustain our ability 
to detect a significant effect of Val66Met genotype (and its 
interaction with APOE) on hippocampal subfields is that 
the studied cohort presents a higher prevalence of BDNF 
Met and APOE-ε4 homozygotes compared with previous 
studies. While most of the studies reported allele frequen-
cies between 0% (studies without MetMet carriers) to 6% 
(Harrisberger et al. 2015), the minor allele frequency in our 
study achieves 23%, which is even higher to the population 
frequency (15–19%, Source: Genome Aggregation Data-
base https ://gnoma d.broad insti tute.org/varia nt/11-27679 
916-C-T). Similarly, the high number of APOE-ε4 carriers 
in the ALFA participants compared to the general popula-
tion (19% vs. 14%, respectively; p < 0.001) has allowed us to 
Fig. 3  Box plot of change in hippocampal subfield volumes between 
BDNF Val66Met (rs6265) genotypes under additive, dominant, reces-
sive and codominant genetic models. Middle line in box represents 
the median; lower box bounds the first quartile; upper box bounds 
the 3rd quartile. Whiskers represent the 95% confidence interval of 
the mean. Open circles are outliers from 95% confidence interval. 
*Significant difference between groups at a nominal level (p < 0.05). 
***Significant difference between groups after multiple comparison 
correction (FDR < 0.05). CA1 cornu ammonis region 1, CA3 cornu 
ammonis region 3, CA4 cornu ammonis region 4, GC-ML-DG gran-
ule cells in the molecular layer of the dentate gyrus, hata hippocam-
pal-amygdaloid transition region, HP hippocampus
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disentangle specific effects in ε4 homozygotes, while most 
studies pool them with heterozygotes in a single APOE-ε4 
carrier group. In our study, the high prevalence of these less 
frequent genotypes has allowed us to achieve a relatively 
higher inferential power, allowing for testing additive, reces-
sive and codominant genetic effects, as well as, gene–gene 
interactions.
Another substantial strength is the use of a high-reso-
lution T1 scan as compared to previous studies, combined 
with the use of the most recent version (v.6.0) of the hip-
pocampal subfield segmentation toolbox in Freesurfer, 
which overcomes significant shortcomings of previous ver-
sions (Iglesias et al. 2015; Wisse et al. 2014; Mueller et al. 
2018). Thus, subfield volumes available for this analysis are 
of substantially better quality, which, combined with a con-
siderably higher sample size, has allowed us to achieve a 
significantly superior statistical power than previous reports. 
Moreover, only a few studies have assessed hippocampal 
subfield volumes and compared them to whole hippocampal 
volumetry, even though the independent genetic variation 
specific to hippocampal subfields (Elman et al. 2019). Thus, 
our analyses based on hippocampal subfields increased the 
sensitivity of the results, which make our study more robust 
and consistent than previous ones.
Finally, in contrast to previous studies in which the diag-
nostic value of hippocampal subfield volumes related to 
Val66Met polymorphism was only assessed by comparing 
patients with psychiatric disorders, our study includes CU 
middle-aged/late-middle-age participants. This is also a rel-
evant strength because the misrepresentation of the general 
population could constitute a bias in the assessment of the 
diagnostic utility of hippocampal subfield volumes, due to 
potential etiologies associated with neurodegenerative pro-
cesses (de Flores et al. 2015).
Altogether, our findings suggest that the BDNF Met allele 
might confer a time-limited resilience, which protects the 
Table 5  Interaction Effects 
Between number of APOE-ε4 
alleles (under additive 
model) and BDNF Val66Met 
polymorphism (under dominant 
genetic model) on hippocampal 
subfields
All models were adjusted by sex, years of education, age and total intracranial volume
CA1 cornu ammonis region 1, CA3 cornu ammonis region 23 CA4 cornu ammonis region 4, GC-ML-DG 
granule cells in the molecular layer of the dentate gyrus, hata hippocampal-amygdaloid transition region, 
HP hippocampus, CI95 confidence interval, FDR95 FDR corrected p value < 0.05
Hippocampal subfield Dominant genetic model
Effect  (mm3) CI 95% Effect (%) p value FDR95%
CA1 − 10.788 (− 52.36, 30.79) − 0.90% 0.611 1
55.535 (− 23.33, 134.4) 4.61% 0.168 1
CA3 10.889 (− 4.31, 26.09) 2.99% 0.161 1
27.425 (− 1.4, 56.25) 7.53% 0.063 0.567
CA4 7.797 (− 6.39, 21.98) 1.71% 0.282 1
33.155 (6.25, 60.06) 7.25% 0.016 0.192
GC-ML-DG 7.94 (− 8.39, 24.27) 1.47% 0.341 1
39.772 (8.79, 70.75) 7.38% 0.012 0.156
Subiculum − 13.434 (− 42.9, 16.03) − 1.65% 0.372 1
25.529 (− 30.36, 81.42) 3.14% 0.371 1
Presubiculum 0.013 (− 21.92, 21.94)  ~ 0% 0.999 1
13.726 (− 27.87, 55.33) 2.26% 0.518 1
Parasubiculum 2.587 (− 3.7, 8.88) 2.05% 0.421 1
2.78 (− 9.15, 14.71) 2.21% 0.648 1
Hippocampal fissure − 1.375 (− 17.1, 14.35) − 0.40% 0.864 1
7.756 (− 22.08, 37.59) 2.26% 0.611 1
Hippoccampal tail 21.561 (− 25.48, 68.6) 2.00% 0.369 1
89.676 (0.45, 178.9) 8.33% 0.05 0.506
Fimbria − 7.8 (− 19.07, 3.47) − 4.46% 0.176 1
8.845 (− 12.54, 30.23) 5.05% 0.418 1
Hata − 0.304 (− 5.25, 4.64) − 0.26% 0.904 1
4.091 (− 5.29, 13.47) 3.47% 0.393 1
Molecular layer − 2.31 (− 33.37, 28.75) − 0.22% 0.884 1
49.911 (− 9.01, 108.83) 4.67% 0.098 0.784
Whole hippocampus 16.151 (− 164.67, 196.97) 0.25% 0.861 1
350.445 (7.43, 693.46) 5.35% 0.046 0.506
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Fig. 4  Differences according BDNF Val66Met genotypes in associa-
tions between APOE-ε4 and a Cornu ammonis region 4 (CA4) sub-
field volume, b Granule cells in the molecular layer of the dentate 
gyrus (GC-ML-DG) subfield volume, c hippocampal tail subfield vol-
ume, and d whole hippocampal volume
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hippocampi from the downstream deleterious effects of age-
ing and/or amyloid accumulation, thus mediating the risk 
effect of APOE-ε4. Hence, these results prompt us to further 
explore hippocampal atrophy rates and cognitive trajectories 
of BDNF Met carriers compared to Val homozygotes, also as 
a function of their APOE genotype and long-term accumula-
tion of amyloid beta.
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